{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:07Z","timestamp":1761871387325,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K24CA208132"],"award-info":[{"award-number":["K24CA208132"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clml.2019.12.003","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:01:09Z","timestamp":1577145669000},"page":"234-243.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-9192","authenticated-orcid":false,"given":"Sharvil P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Andrew","family":"Harkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0489","authenticated-orcid":false,"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.003_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2019.12.003_bib2","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.003_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.003_bib4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.003_bib5","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","article-title":"Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era","volume":"25","author":"Vaidya","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.12.003_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2019.12.003_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.003_bib9","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","article-title":"Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.clml.2019.12.003_bib11","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1002\/cncr.30740","article-title":"Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: where do we go from here?","volume":"123","author":"Koff","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.003_bib12","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.12.003_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2019.12.003_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2019.12.003_bib15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.12.003_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.12.003_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2019.12.003_bib18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.003_bib19","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2019.12.003_bib20","doi-asserted-by":"crossref","first-page":"D1068","DOI":"10.1093\/nar\/gkx1143","article-title":"DGIdb 3.0: a redesign and expansion of the drug-gene interaction database","volume":"46","author":"Cotto","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2019.12.003_bib21","doi-asserted-by":"crossref","first-page":"D985","DOI":"10.1093\/nar\/gkw1055","article-title":"Open Targets: a platform for therapeutic target identification and validation","volume":"45","author":"Koscielny","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2019.12.003_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/gix015","article-title":"Enhancing knowledge discovery from cancer genomics data with Galaxy","volume":"6","author":"Albuquerque","year":"2017","journal-title":"Gigascience"},{"key":"10.1016\/j.clml.2019.12.003_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3960\/jslrt.56.71","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"56","author":"Dobashi","year":"2016","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.clml.2019.12.003_bib24","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1158\/1078-0432.CCR-16-0232","article-title":"Precision medicine for diffuse large B-cell lymphoma","volume":"22","author":"Lim","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.12.003_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gcc.22328","article-title":"Whole exome sequencing of relapsed\/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma","volume":"55","author":"Mareschal","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2019.12.003_bib26","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.12.003_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib28","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1038\/bcj.2015.69","article-title":"Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma","volume":"5","author":"Novak","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.12.003_bib29","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clml.2014.01.001","article-title":"Deep sequencing reveals lack of a clonal relationship between a metachronous classical Hodgkin and diffuse large B-cell lymphoma","volume":"14","author":"Siddiqi","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.12.003_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clml.2019.12.003_bib31","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1074\/jbc.M115.687251","article-title":"Analysis of the effects of the Bruton's tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fc\u03b3 receptor (Fc\u03b3R) function","volume":"291","author":"Ren","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90196","article-title":"Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations","volume":"2","author":"Mondello","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2019.12.003_bib33","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","article-title":"The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 in in\u00a0vitro and in\u00a0vivo models of MYC+\/BCL2+ double hit lymphoma","volume":"37","author":"Esteve-Arenys","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2019.12.003_bib34","doi-asserted-by":"crossref","first-page":"eaan8723","DOI":"10.1126\/scitranslmed.aan8723","article-title":"Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC\/BCL2 double-hit B cell lymphoma","volume":"10","author":"Rav\u00e0","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2019.12.003_bib35","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.12.003_bib36","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/leu.2015.99","article-title":"Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1","volume":"29","author":"Li","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.12.003_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2011.12.012","article-title":"Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion","volume":"142","author":"Barr","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2019.12.003_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.12.003_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.clml.2019.12.003_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/2472555218786165","article-title":"Homogeneous BTK occupancy assay for pharmacodynamic assessment of tirabrutinib (GS-4059\/ONO-4059) target engagement","volume":"23","author":"Yu","year":"2018","journal-title":"SLAS Discov"},{"key":"10.1016\/j.clml.2019.12.003_bib41","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib43","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.003_bib44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.003_bib45","doi-asserted-by":"crossref","first-page":"e7980","DOI":"10.15252\/embj.201797980","article-title":"Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells","volume":"37","author":"He","year":"2018","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2019.12.003_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2019.12.003_bib47","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","article-title":"Cell cycle deregulation in B-cell lymphomas","volume":"101","author":"Sanchez-Beato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2015.08.006","article-title":"TP53 dysfunction in diffuse large B-cell lymphoma","volume":"97","author":"Lu","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.12.003_bib49","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib50","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2019.12.003_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040127","article-title":"Responses to the selective Bruton's tyrosine kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in diffuse large B-cell lymphoma cell lines","volume":"10","author":"Kozaki","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2019.12.003_bib52","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2019.12.003_bib53","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2019.12.003_bib54","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.003_bib55","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3892\/ol.2015.3038","article-title":"Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab","volume":"9","author":"Zhao","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2019.12.003_bib56","doi-asserted-by":"crossref","first-page":"51494","DOI":"10.18632\/oncotarget.9860","article-title":"Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones","volume":"7","author":"Melchardt","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2019.12.003_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110459","article-title":"Mutational evolution in relapsed diffuse large B-cell lymphoma","volume":"10","author":"Nijland","year":"2018","journal-title":"Cancers (Basel)"},{"author":"Johnson","key":"10.1016\/j.clml.2019.12.003_bib58"},{"author":"Staudt","key":"10.1016\/j.clml.2019.12.003_bib59"},{"key":"10.1016\/j.clml.2019.12.003_bib60","first-page":"989","article-title":"Precision medicine in diffuse large B-cell lymphoma: hitting the target","volume":"100","author":"Vermaat","year":"2015","journal-title":"Haematologica"},{"author":"Younes","key":"10.1016\/j.clml.2019.12.003_bib61"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019322153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019322153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:50Z","timestamp":1761870830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019322153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S2152265019322153"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}